Researchers in Nature look at what shapes the evolution of a non-ribosomal peptide, pointing to drift, selection and recombination bias as the drivers.
Recap by typeshit. Full story at Nature.
The REDEFINE 1 data covered 2,309 women, with placebo at 3%. In the REDEFINE 4 head-to-head, tirzepatide matched or slightly beat it.
Superpower says the drug carries radiation straight to cancer cells and cites a phase 3 trial showing a 79% lower risk of progression or death. A 14-part thread.
Australian experts note about half a million people there use GLP-1 drugs for diabetes alone, and lay out what new users should keep in mind about nutrition.
A herpetology-themed clip from PBS points to reptiles as part of the story behind today's GLP-1 medications. Short and light, but a fun bit of history.
The FDA plan would let pharmacies compound peptides like BPC-157 under enforcement discretion, even though agency scientists say safety is unproven.
Medscape covers research tying GLP-1 drug use to lower alcohol consumption. Tap through for the study details and what researchers found.
Loading…